Migraine treatment with rizatriptan and non-triptan usual care medications: A pharmacy-based study

被引:8
|
作者
Cady, R
Martin, V
Adelman, J
Diamond, M
Sajjan, S
Hu, XH
机构
[1] Merck & Co Inc, Outcomes Res & Management, W Point, PA 19486 USA
[2] Primary Care Network Inc, Headache Care Ctr, Springfield, MO USA
[3] Univ Cincinnati, Div Gen Internal Med, Cincinnati, OH USA
[4] Headache Wellness Ctr, Greensboro, NC USA
[5] Diamond Headache Clin Ltd, Chicago, IL USA
来源
HEADACHE | 2004年 / 44卷 / 09期
关键词
migraine; migraine acute treatment; rizatriptan; non-triptan usual care medications;
D O I
10.1111/j.1526-4610.2004.04172.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective.-To compare the effectiveness of rizatriptan to other non-triptan medications in the relief of migraine headache in usual care settings. Background.-Although rizatriptan has been shown to provide effective relief of migraine symptoms in clinical trials, limited data exist directly comparing its effectiveness with non-triptan medications. Methods.-Migraineurs aged 18 to 55 who had been prescribed a new antimigraine drug (rizatriptan 10 mg or a selected class of non-triptan oral medications) were recruited to participate in the study through a national retail pharmacy chain. Participants completed a baseline questionnaire at the enrollment and reported their treatment experiences by filling out the treatment diary after using the newly prescribed medication. The treatment outcomes of patients receiving rizatriptan were compared with those receiving non-triptan medications. Logistic regression analysis was applied to test statistical significance with adjustment for potential confounding factors. Results.-Of the 728 patients who entered the study, 693 (95.2%) completed the treatment diary. Patients treated with rizatriptan (192) and non-triptans (501) reported the following outcomes, respectively-onset of headache relief within 30 minutes post-dose: 25% versus 18%; self-defined significant headache relief within 2 hours post-dose: 71% versus 54%; pain free or mild pain at 2 hours post-dose: 58% versus 47%; completely symptom-free within 2 hours of post-dose: 32% versus 20%; return to usual activities within 2 hours post-dose: 39% versus 35%; and satisfied with treatment: 67% versus 55% (P < .05 in all comparisons with exception of returning to usual activities). Conclusion.-Rizatriptan was significantly more effective than non-triptans in the relief of migraine headaches for patients obtaining prescribed migraine medications from a retail pharmacy. Additional studies at other usual care settings may be needed to confirm the findings.
引用
收藏
页码:900 / 907
页数:8
相关论文
共 50 条
  • [1] Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting
    Baos, V
    Serrano, A
    Torrecilla, M
    Bertral, C
    Caloto, MT
    Nocea, G
    Gerth, WC
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (09) : 761 - 768
  • [2] Migraine treatment with rizatriptan and usual care medications: An open-label crossover study
    Hu, XH
    Barlas, S
    Solomon, G
    NEUROLOGY, 2006, 66 (05) : A43 - A43
  • [3] Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations
    Ingram, Ellen E.
    Bocklud, Brooke E.
    Corley, Sarah C.
    Granier, Mallory A.
    Neuchat, Elisa E.
    Ahmadzadeh, Shahab
    Shekoohi, Sahar
    Kaye, Alan D.
    CURRENT PAIN AND HEADACHE REPORTS, 2023, 27 (10) : 497 - 502
  • [4] Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations
    Ellen E. Ingram
    Brooke E. Bocklud
    Sarah C. Corley
    Mallory A. Granier
    Elisa E. Neuchat
    Shahab Ahmadzadeh
    Sahar Shekoohi
    Alan D. Kaye
    Current Pain and Headache Reports, 2023, 27 : 497 - 502
  • [5] Rizatriptan versus usual care in long-term treatment of migraine
    Silberstein, SD
    NEUROLOGY, 2000, 55 (09) : S25 - S28
  • [6] Migraine treatment outcomes with rizatriptan in triptan-naive patients: A naturalistic study
    Solomon, S
    Frishberg, B
    Hu, XH
    Markson, L
    Berger, M
    CLINICAL THERAPEUTICS, 2001, 23 (06) : 886 - 900
  • [7] Cost-effectiveness study of rizatriptan vs. usual care in the treatment of migraine in Canada
    Desjardins, B
    Thompson, M
    Ferko, N
    Marceau, C
    Gawel, M
    VALUE IN HEALTH, 2003, 6 (06) : 762 - 763
  • [8] Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications
    Alan M. Rapoport
    Jo H. Bonner
    Tamar Lin
    Dagan Harris
    Yaron Gruper
    Alon Ironi
    Robert P. Cowan
    The Journal of Headache and Pain, 2019, 20
  • [9] Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications
    Rapoport, Alan M.
    Bonner, Jo H.
    Lin, Tamar
    Harris, Dagan
    Gruper, Yaron
    Ironi, Alon
    Cowan, Robert P.
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1):
  • [10] REAL-WORLD IMPACT OF MIGRAINE ON CANADIANS' PRODUCTIVITY: A PHARMACY-BASED STUDY
    Patenaude, J.
    Laliberte, Gouault A.
    Beauchemin, C.
    Lachaine, J.
    VALUE IN HEALTH, 2023, 26 (12) : S482 - S483